Spots Global Cancer Trial Database for myelofibrosis
Every month we try and update this database with for myelofibrosis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002) | NCT03136185 | Myelofibrosis Post-polycythem... Post-essential ... Primary Myelofi... | Bomedemstat | 18 Years - | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | |
| A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers | NCT04328844 | Solid Tumor, Ad... Non-Hodgkin Lym... NSCLC Myelofibrosis Uveal Melanoma | IOA-244 Avelumab Inject... Pemetrexed Cisplatin Ruxolitinib | 18 Years - | iOnctura | |
| A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | NCT02440685 | Lymphoma, Large... Lymphoma, Mantl... Lymphoma, Folli... Cancer Neoplasm Tumor Lymphoma, Malig... Lymphoma, B-cel... Lymphoma, Non-H... B-Cell Chronic ... B-Cell Leukemia... B-Lymphocytic L... Chronic Lymphoc... Leukemia, Lymph... Leukemia, Lymph... Myelofibrosis Chronic Idiopat... Idiopathic Myel... Lymphoma, T Cel... Peripheral T-Ce... T-Cell Lymphoma... | ASN002 Dose Esc... ASN002 RD | 18 Years - | Asana BioSciences | |
| CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant | NCT06059391 | Acute Lymphobla... Acute Myeloid L... Chronic Lymphoc... Chronic Myeloid... Hematopoietic a... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloproliferat... Non-Hodgkin Lym... | Allogeneic Hema... Biospecimen Col... Granulocyte Col... Hematopoietic C... Multi-peptide C... Pheresis Placebo Adminis... Stem Cell Mobil... | 18 Years - | City of Hope Medical Center | |
| European Registry for Myeloproliferative Neoplasms (MPNs) - Update of ERNEST Study | NCT04153305 | Myelofibrosis | 18 Years - | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | ||
| Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis | NCT04454658 | Myelofibrosis (... | ABBV-744 Navitoclax Ruxolitinib | 18 Years - | AbbVie | |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | NCT03452774 | Cancer, Metasta... Cancer Cancer of Pancr... Cancer of Liver Cancer of Stoma... Cancer Liver Cancer of Rectu... Cancer of Kidne... Cancer of Esoph... Cancer of Cervi... Cancer of Colon Cancer of Laryn... Cancer, Lung Cancer, Breast Cancer, Advance... Cancer Prostate Cancer of Neck Cancer of Skin Neuroendocrine ... Carcinoma Mismatch Repair... BRCA Gene Rearr... Non Hodgkin Lym... Leukemia Non Small Cell ... Cholangiocarcin... Glioblastoma Central Nervous... Melanoma Urothelial Carc... Bladder Cancer Ovarian Cancer Endometrial Can... Testicular Canc... Breast Cancer COVID Myelofibrosis Myeloproliferat... Myeloproliferat... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Myelodysplastic... | Clinical Trial ... | - | Massive Bio, Inc. | |
| COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial | NCT00952289 | MPN (Myeloproli... | Ruxolitinib Placebo | 18 Years - | Incyte Corporation | |
| Expanded Access to Navitoclax | NCT03592576 | Myelofibrosis Acute Lymphocyt... Lymphoblastic L... | Navitoclax Venetoclax | 4 Years - | AbbVie | |
| Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis | NCT04217356 | Myelofibrosis High-Risk Cance... Bone Marrow Can... | Hematopoietic s... Ruxolitinib Hydroxyurea | 18 Years - 70 Years | University Health Network, Toronto | |
| A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis | NCT03165734 | Primary Myelofi... Post-polycythem... Post-essential ... | Pacritinib Physician's Cho... | 18 Years - | CTI BioPharma | |
| Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy | NCT01956799 | Myelodysplasia Myelofibrosis Aplastic Anemia | 18 Years - | Fondazione Italiana Sindromi Mielodisplastiche-ETS | ||
| Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia | NCT02055781 | Primary Myelofi... Post-polycythem... Post-essential ... | Pacritinib Best Available ... | 18 Years - | CTI BioPharma | |
| To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213) | NCT04629508 | Myelofibrosis Polycythemia Ve... Thrombocythemia | itacitinib | 18 Years - | Incyte Corporation | |
| URMC Related Haplo-identical Donor BMT | NCT02660281 | Hematological D... Immune Deficien... Solid Tumors Myelofibrosis Multiple Myelom... Lymphoma | Total Body Irra... Fludarabine Pre-Stem Cell I... Pre-Stem Cell I... Busulfan Melphalan Stem Cell Infus... Post-Stem Cell ... Post-Stem Cell ... Thiotepa | 6 Months - 75 Years | University of Rochester | |
| Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation | NCT03602898 | Acute Lymphobla... Acute Myeloid L... Chronic Myelomo... Chronic Phase C... Hematopoietic a... Myelodysplastic... Myelofibrosis Myeloproliferat... Recurrent Acute... Recurrent Hodgk... Recurrent Non-H... Refractory Acut... Therapy-Related... | Anti-Thymocyte ... Busulfan Cyclophosphamid... Cyclosporine Fludarabine Pho... Methotrexate Peripheral Bloo... Quality-of-Life... Questionnaire A... Tacrolimus Total-Body Irra... | - 65 Years | Fred Hutchinson Cancer Center | |
| A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers | NCT04328844 | Solid Tumor, Ad... Non-Hodgkin Lym... NSCLC Myelofibrosis Uveal Melanoma | IOA-244 Avelumab Inject... Pemetrexed Cisplatin Ruxolitinib | 18 Years - | iOnctura | |
| URMC Related Haplo-identical Donor BMT | NCT02660281 | Hematological D... Immune Deficien... Solid Tumors Myelofibrosis Multiple Myelom... Lymphoma | Total Body Irra... Fludarabine Pre-Stem Cell I... Pre-Stem Cell I... Busulfan Melphalan Stem Cell Infus... Post-Stem Cell ... Post-Stem Cell ... Thiotepa | 6 Months - 75 Years | University of Rochester | |
| SARS-CoV-2 Donor-Recipient Immunity Transfer | NCT04666025 | Accelerated Pha... Acute Lymphobla... Acute Myeloid L... Chronic Lymphoc... Chronic Phase C... COVID-19 Infect... Hematopoietic a... Hodgkin Lymphom... Lymphoblastic L... Myelodysplastic... Myelofibrosis Myeloproliferat... Non-Hodgkin Lym... | Biospecimen Col... Diagnostic Labo... Electronic Heal... Questionnaire A... | 18 Years - | City of Hope Medical Center | |
| Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant | NCT01244906 | Hematologic Neo... | Allogeneic Hema... | 18 Years - 75 Years | Northside Hospital, Inc. | |
| Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients | NCT02877082 | Acute Leukemia Chronic Lymphoc... Chronic Myeloge... Diffuse Large B... Follicular Lymp... Graft Versus Ho... Mantle Cell Lym... Marginal Zone L... Myelodysplastic... Myelofibrosis Myeloproliferat... Small Lymphocyt... | Thymoglobulin Bortezomib Tacrolimus | 18 Years - 75 Years | Emory University | |
| Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome | NCT00475020 | Myelofibrosis | Busulfan Fludarabine Thymoglobulin (... | - 75 Years | M.D. Anderson Cancer Center | |
| Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis | NCT01731951 | Primary Myelofi... Secondary Myelo... Myeloid Maligna... | Imetelstat | 18 Years - | Geron Corporation | |
| Correlative Biomarker Study in Patients With Myeloproliferative Disorders | NCT00665067 | Myeloproliferat... Myelofibrosis Idiopathic Myel... Essential Throm... Polycythemia Ve... | 18 Years - | Icahn School of Medicine at Mount Sinai | ||
| Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant | NCT05031897 | Acute Lymphobla... Acute Myeloid L... Aplastic Anemia Chronic Lymphoc... Chronic Myelomo... Essential Throm... Hematopoietic a... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloid Leukemi... Myeloid Neoplas... Non-Hodgkin Lym... Plasma Cell Mye... Polycythemia Ve... Small Lymphocyt... | Hematopoietic C... Mycophenolate M... Tacrolimus Cyclophosphamid... Total-Body Irra... Donor Lymphocyt... Fludarabine Melphalan | 18 Years - | Thomas Jefferson University | |
| HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation | NCT04464889 | Acute Myeloid L... Acute Lymphoid ... Myelodysplastic... Myeloproliferat... Chronic Myeloid... Myelofibrosis Multiple Myelom... Malignant Lymph... | MDG1021 dose 1 MDG1021 dose 2 MDG1021 dose 3 MDG1021 optimal... | 18 Years - | Medigene AG | |
| Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias | NCT00522990 | Acute Myeloid L... Acute Lymphobla... Chronic Myeloid... Myelodysplastic... Myelofibrosis | AT9283 | 18 Years - | Astex Pharmaceuticals, Inc. | |
| Anti-TGF-beta Therapy in Patients With Myelofibrosis | NCT01291784 | Myelofibrosis Primary Myelofi... Polycythemia Ve... Post-essential ... | monoclonal anti... | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients | NCT01340651 | Myelofibrosis | Ruxolitinib | 18 Years - | Incyte Corporation | |
| An Open-label Phase II Study of Lorvotuzumab Mertansine | NCT02420873 | Leukemia | Lorvotuzumab Me... | 18 Years - | M.D. Anderson Cancer Center | |
| Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis | NCT02805868 | Myelofibrosis Polycythemia Ve... Primary Myelofi... Thrombocytopeni... | Bone Marrow Asp... Laboratory Biom... Siltuximab | 18 Years - | Northwestern University | |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | NCT03314974 | Acute Leukemia Acute Myeloid L... Acute Lymphobla... Lymphoma Chronic Myeloge... Plasma Cell Leu... Myeloproliferat... Myelofibrosis Myelodysplasia Refractory Anem... High Risk Anemi... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large C... Lymphoblastic L... Burkitt Lymphom... High Grade Non-... Multiple Myelom... Juvenile Myelom... Biphenotypic/Un... MRD Positive Le... Natural Killer ... Acquired Bone M... | HSCT with TBI R... HSCT with Non-T... | - 60 Years | Masonic Cancer Center, University of Minnesota | |
| Correlative Biomarker Study in Patients With Myeloproliferative Disorders | NCT00665067 | Myeloproliferat... Myelofibrosis Idiopathic Myel... Essential Throm... Polycythemia Ve... | 18 Years - | Icahn School of Medicine at Mount Sinai | ||
| Creation of Bone Marrow Microenvironment for Treatment of Myelodysplastic Syndrome (MDS) in Conjunction With Allogeneic Stem Cell Transplantation | NCT00148980 | Myelodysplastic... Myelofibrosis | DBM for creatio... | 18 Years - | Hadassah Medical Organization | |
| Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis | NCT01433445 | Idiopathic Myel... Post Essential ... Post Polycythem... | panobinostat ruxolitinib | 18 Years - | Novartis | |
| Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States | NCT00997386 | Hematologic Neo... Multiple Myelom... Anemia, Aplasti... Hemoglobinuria,... Myelofibrosis | busulfan, and m... | 18 Years - 75 Years | University of Arizona | |
| Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis | NCT04676529 | Myelofibrosis | PXS-5505 | 18 Years - | Syntara | |
| TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation | NCT01300611 | Double Cord Blo... Acute Myelogeno... Myelodysplastic... Myelofibrosis Acute Lymphobla... Chronic Myelocy... Non Hodgkins Ly... Hodgkins Lympho... Chronic Lymphoc... | TXA127 300 mcg/... TXA127 1000 mcg... | 18 Years - 60 Years | Tarix Pharmaceuticals | |
| A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib | NCT03755518 | Primary Myelofi... Post-Polycythem... Myelofibrosis Post-essential ... | FEDRATINIB | 18 Years - | Celgene | |
| Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study | NCT05972577 | Acute Lymphobla... Acute Myeloid L... Aplastic Anemia Chronic Lymphoc... Chronic Myeloge... Hematopoietic a... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloproliferat... Non-Hodgkin Lym... Plasma Cell Mye... | Health Promotio... Medical Device ... Quality-of-Life... Questionnaire A... | 60 Years - | Ohio State University Comprehensive Cancer Center | |
| Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States | NCT00997386 | Hematologic Neo... Multiple Myelom... Anemia, Aplasti... Hemoglobinuria,... Myelofibrosis | busulfan, and m... | 18 Years - 75 Years | University of Arizona | |
| Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants | NCT00606437 | Lymphoma Myeloma Leukemia Myelodysplasia Solid Tumors Hodgkin's Disea... Myelofibrosis | Total Body Irra... | 14 Years - 65 Years | Duke University | |
| A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms | NCT05936359 | Myeloproliferat... | INCA033989 Ruxolitinib | 18 Years - | Incyte Corporation | |
| The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase | NCT03907436 | Myeloproliferat... Myeloproliferat... Myelofibrosis Polycythemia Ve... Essential Throm... | USDA Diet Mediterranean D... | 18 Years - | University of California, Irvine | |
| Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG | NCT02916979 | Leukemia, Lymph... Leukemia, Myelo... Myelodysplastic... Myelofibrosis Lymphoma, Malig... Multiple Myelom... Waldenstrom Mac... | Fludarabine Busulfan Rabbit ATG Methotrexate | 18 Years - 75 Years | Dartmouth-Hitchcock Medical Center | |
| Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation | NCT00720629 | Graft Versus Ho... | Visilizumab Tacrolimus Methotrexate Antithymocyte g... Tacrolimus Methotrexate | 18 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia | NCT04896112 | Acute Myeloid L... Primary Myelofi... Post-polycythem... Post-essential ... Polycythemia Ve... | LNK01002 | 18 Years - 99 Years | Lynk Pharmaceuticals Co., Ltd | |
| Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation | NCT00720629 | Graft Versus Ho... | Visilizumab Tacrolimus Methotrexate Antithymocyte g... Tacrolimus Methotrexate | 18 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer | NCT00975975 | Acute Myelogeno... Acute Lymphocyt... Chronic Myeloge... Chronic Lymphoc... Myelodysplasia Non-Hodgkin's L... Hodgkin's Disea... Multiple Myelom... Myelofibrosis Anemia, Aplasti... Hemoglobinuria,... | Basiliximab | 18 Years - | Indiana University | |
| Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms | NCT01520220 | Myeloproliferat... Polycythemia Ve... Essential Throm... Myelofibrosis | LY2784544 | 18 Years - | Eli Lilly and Company | |
| Myelofibrosis and Essential Thrombocythemia Observational Study (MOST) | NCT02953704 | MPN (Myeloproli... | 18 Years - | Incyte Corporation | ||
| Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence | NCT01178281 | Primary Myelofi... MPN-associated ... | Pomalidomide 0.... Placebo Pomalidomide | 18 Years - | Celgene | |
| An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib | NCT04485260 | Myelofibrosis | KRT-232 Ruxolitinib | 18 Years - 99 Years | Kartos Therapeutics, Inc. | |
| HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | NCT06001385 | Acute Lymphobla... Acute Myeloid L... Acute Leukemia Myelodysplastic... Chronic Myeloid... Chronic Lymphoc... Myeloproliferat... Lymphoma Chronic Myelomo... Pro-Lymphocytic... Myelofibrosis | Busulfan Fludarabine PBSC Hematopoie... Post-Transplant... Mesna Tacrolimus Mycophenolate M... Patient Reporte... Melphalan Total-body irra... Cyclophosphamid... | 18 Years - | Center for International Blood and Marrow Transplant Research | |
| Study of DISC-0974 in Participants With Myelofibrosis and Anemia | NCT05320198 | Myelofibrosis; ... Anemia Myelofibrosis Myelofibrosis D... Primary Myelofi... Post-essential ... | DISC-0974 | 18 Years - | Disc Medicine, Inc | |
| Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN) | NCT02410551 | Myeloproliferat... | Pacritinib Busulfan Questionnaires Phone Calls Allogeneic Stem... Fludarabine | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| A Safety Study of XL019 in Adults With Myelofibrosis | NCT00522574 | Myeloproliferat... Myelofibrosis Polycythemia Ve... Thrombocythemia... | XL019 | 18 Years - | Exelixis | |
| Research Tissue Bank | NCT00666549 | Myelofibrosis Idiopathic Myel... Essential Throm... Polycythemia Ve... | 18 Years - | Icahn School of Medicine at Mount Sinai | ||
| Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis | NCT04676529 | Myelofibrosis | PXS-5505 | 18 Years - | Syntara | |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | NCT03314974 | Acute Leukemia Acute Myeloid L... Acute Lymphobla... Lymphoma Chronic Myeloge... Plasma Cell Leu... Myeloproliferat... Myelofibrosis Myelodysplasia Refractory Anem... High Risk Anemi... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large C... Lymphoblastic L... Burkitt Lymphom... High Grade Non-... Multiple Myelom... Juvenile Myelom... Biphenotypic/Un... MRD Positive Le... Natural Killer ... Acquired Bone M... | HSCT with TBI R... HSCT with Non-T... | - 60 Years | Masonic Cancer Center, University of Minnesota | |
| Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients | NCT01398462 | Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Myelofibrosis | CWP232291 | 18 Years - | JW Pharmaceutical | |
| Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis | NCT04472598 | Myelofibrosis (... | Navitoclax Ruxolitinib Placebo for Nav... | 18 Years - | AbbVie | |
| Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant | NCT00354120 | Acute Myeloblas... Lymphoblastic L... Myelodysplasia Chronic Myeloid... Myelofibrosis Lympho-prolifer... | Alentuzumab Globulina antil... | 18 Years - 65 Years | Gruppo Italiano Trapianto di Midollo Osseo | |
| Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy | NCT01956799 | Myelodysplasia Myelofibrosis Aplastic Anemia | 18 Years - | Fondazione Italiana Sindromi Mielodisplastiche-ETS | ||
| Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant | NCT02506933 | Accelerated Pha... Acute Lymphobla... Acute Myeloid L... Chronic Lymphoc... Chronic Phase C... Cytomegaloviral... Hodgkin Lymphom... Lymphadenopathy Lymphoblastic L... Myelodysplastic... Myelofibrosis Myeloproliferat... Non-Hodgkin Lym... | Laboratory Biom... Multi-peptide C... Placebo | 18 Years - 75 Years | City of Hope Medical Center | |
| A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF | NCT01787552 | Primary Myelofi... Thrombocytosis Essential Throm... Polycythemia Ve... Myeloproliferat... Bone Marrow Dis... Hematologic Dis... Blood Coagulati... Blood Platelet ... Hemorrhagic Dis... | LDE225 INC424 | 18 Years - | Novartis | |
| Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source | NCT02167958 | Leukemia MDS Myelofibrosis Lymphoma | Fludarabine Cyclophosphamid... Mesna Total Body Irra... Hematopoietic s... Tacrolimus Mycophenolate G-CSF | 18 Years - 70 Years | University of Pittsburgh | |
| A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis | NCT00745550 | Myelofibrosis Myeloproliferat... Polycythemia Ve... Essential Throm... | SB1518 | 18 Years - | S*BIO | |
| A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies | NCT00719836 | Acute Myelogeno... Chronic Myeloge... Chronic Myelomo... Myelodysplastic... Myelofibrosis | SB1518 | 18 Years - | S*BIO | |
| Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) | NCT01167166 | Acute Myelocyti... Acute Lymphocyt... Myeloproliferat... Chronic Myeloid... | rigosertib | 18 Years - | Traws Pharma, Inc. | |
| A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) | NCT04173494 | Primary Myelofi... Post-polycythem... Post-essential ... | Momelotinib Placebo to matc... Danazol Placebo to matc... | 18 Years - | Sierra Oncology LLC - a GSK company | |
| CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms | NCT03566446 | Myeloproliferat... Essential Throm... Myelofibrosis | CALRLong36 pept... | 18 Years - | Herlev Hospital | |
| Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. | NCT04866056 | Myelodysplastic... Myeloproliferat... Myelofibrosis | Jaktinib azacitidine | 18 Years - | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms | NCT03878199 | Essential Throm... Myelofibrosis Myeloproliferat... Polycythemia Ve... Secondary Acute... | Allogeneic Hema... Liposome-encaps... Ruxolitinib | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation | NCT01300611 | Double Cord Blo... Acute Myelogeno... Myelodysplastic... Myelofibrosis Acute Lymphobla... Chronic Myelocy... Non Hodgkins Ly... Hodgkins Lympho... Chronic Lymphoc... | TXA127 300 mcg/... TXA127 1000 mcg... | 18 Years - 60 Years | Tarix Pharmaceuticals | |
| Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients | NCT01398462 | Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Myelofibrosis | CWP232291 | 18 Years - | JW Pharmaceutical | |
| Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis | NCT04480086 | Myelofibrosis (... | Mivebresib Navitoclax Ruxolitinib | 18 Years - | AbbVie | |
| Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) | NCT03645824 | Myelofibrosis | Pacritinib | 18 Years - 70 Years | Stichting Hemato-Oncologie voor Volwassenen Nederland | |
| Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis | NCT00509899 | Myelofibrosis Polycythemia Ve... Thrombocytosis | Ruxolitinib | 18 Years - | Incyte Corporation | |
| A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis | NCT00631462 | Myelofibrosis | TG101348 | 18 Years - | TargeGen |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
